Formenti et al. investigated the potential mechanism through which combination of RT (6 Gy × 5 or 9 Gy × 3 delivered to 1 metastatic site) and ipilimumab, an anti-CTLA-4 monoclonal antibody, can trigger abscopal responses in metastatic non-small cell lung carcinoma patients [7]. Here, CTLA4 is linked to non-small cell lung carcinoma.